Alumis Inc. (NASDAQ:ALMS - Free Report) - Analysts at Leerink Partnrs issued their Q2 2025 EPS estimates for Alumis in a research report issued on Sunday, March 23rd. Leerink Partnrs analyst T. Smith anticipates that the company will post earnings of ($1.48) per share for the quarter. The consensus estimate for Alumis' current full-year earnings is ($8.51) per share. Leerink Partnrs also issued estimates for Alumis' Q3 2025 earnings at ($1.38) EPS, Q4 2025 earnings at ($1.28) EPS, FY2025 earnings at ($5.46) EPS, FY2026 earnings at ($5.19) EPS, FY2027 earnings at ($6.13) EPS, FY2028 earnings at ($3.99) EPS and FY2029 earnings at ($2.04) EPS.
ALMS has been the topic of several other research reports. Oppenheimer began coverage on Alumis in a research note on Thursday, January 30th. They issued an "outperform" rating and a $32.00 price target on the stock. Cantor Fitzgerald reissued an "overweight" rating on shares of Alumis in a research report on Thursday, March 20th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $15.00 price target on shares of Alumis in a research report on Wednesday. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $26.00.
Get Our Latest Analysis on Alumis
Alumis Trading Up 20.0 %
Shares of NASDAQ:ALMS traded up $0.94 during midday trading on Wednesday, reaching $5.64. 1,623,981 shares of the company were exchanged, compared to its average volume of 285,901. Alumis has a fifty-two week low of $3.18 and a fifty-two week high of $13.53. The stock has a fifty day simple moving average of $5.39 and a two-hundred day simple moving average of $8.31.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of the stock. Foresite Capital Management VI LLC acquired a new stake in shares of Alumis in the 4th quarter valued at approximately $33,033,000. Samsara BioCapital LLC bought a new stake in Alumis during the third quarter worth $34,886,000. Geode Capital Management LLC acquired a new stake in Alumis in the third quarter valued at $3,266,000. Norges Bank bought a new position in shares of Alumis in the 4th quarter valued at about $1,606,000. Finally, Foresite Capital Management V LLC increased its stake in shares of Alumis by 3.5% during the 4th quarter. Foresite Capital Management V LLC now owns 5,779,348 shares of the company's stock worth $45,426,000 after purchasing an additional 194,459 shares during the last quarter.
About Alumis
(
Get Free Report)
Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.
See Also
Before you consider Alumis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alumis wasn't on the list.
While Alumis currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
